{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:59:22Z","timestamp":1760014762276,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Theor Biol Med Model"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Associations between disease characteristics and payer-relevant outcomes can be difficult to establish for rare and progressive chronic diseases with sparse available data. We developed an exploratory bridging model to predict premature mortality from disease characteristics, and using inclusion body myositis (IBM) as a representative case study.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Candidate variables that may be potentially associated with premature mortality were identified by disease experts and from the IBM literature. Interdependency between candidate variables in IBM patients were assessed using existing patient-level data. A Bayesian survival model for the IBM population was developed with identified variables as predictors for premature mortality in the model. For model selection and external validation, model predictions were compared to published mortality data in IBM patient cohorts. After validation, the final model was used to simulate the increased risk of premature death in IBM patients. Baseline survival was based on age- and gender-specific survival curves for the general population in Western countries as reported by the World Health Organisation.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Presence of dysphagia, aspiration pneumonia, falls, being wheelchair-bound and 6-min walking distance (6MWD in meters) were identified as candidate variables to be used as predictors for premature mortality based on inputs received from disease experts and literature. There was limited correlation between these functional performance measures, which were therefore treated as independent variables in the model. Based on the Bayesian survival model, among all candidate variables, presence of dysphagia and decrease in 6MWD [m] were associated with poorer survival with contributing hazard ratios (HR) 1.61 (95% credible interval [CrI]: 0.84\u20133.50) and 2.48 (95% CrI: 1.27\u20135.00) respectively. Excess mortality simulated in an IBM cohort vs. an age- and gender matched general-population cohort was 4.03 (95% prediction interval 1.37\u201310.61).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>For IBM patients, results suggest an increased risk of premature death compared with the general population of the same age and gender. In the absence of hard data, bridging modelling generated survival predictions by combining relevant information. The methodological principle would be applicable to the analysis of associations between disease characteristics and payer-relevant outcomes in progressive chronic and rare diseases. Studies with lifetime follow-up would be needed to confirm the modelling results.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12976-019-0114-4","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:06:50Z","timestamp":1573085210000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and validation of a Bayesian survival model for inclusion body myositis"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-4456","authenticated-orcid":false,"given":"Gorana","family":"Capkun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubhro","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harsh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Obadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"de Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valery","family":"Risson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Billy","family":"Amzal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,7]]},"reference":[{"key":"114_CR1","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1056\/NEJM198806093182329","volume":"318","author":"PM Ellwood","year":"1988","unstructured":"Ellwood PM. Shattuck lecture--outcomes management. A technology of patient experience. N Engl J Med. 1988;318:1549\u201356.","journal-title":"N Engl J Med"},{"key":"114_CR2","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/jnnp.2009.173823","volume":"80","author":"AA Amato","year":"2009","unstructured":"Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry. 2009;80:1186\u201393.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"114_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.410380504","volume":"38","author":"RC Griggs","year":"1995","unstructured":"Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38:705\u201313.","journal-title":"Ann Neurol"},{"key":"114_CR4","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1093\/brain\/awr213","volume":"134","author":"O Benveniste","year":"2011","unstructured":"Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, Maisonobe T, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134:3176\u201384.","journal-title":"Brain."},{"key":"114_CR5","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1093\/brain\/awr217","volume":"134","author":"FM Cox","year":"2011","unstructured":"Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJGM, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134:3167\u201375.","journal-title":"Brain."},{"key":"114_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3233\/JND-150138","volume":"3","author":"MA Price","year":"2016","unstructured":"Price MA, Barghout V, Benveniste O, Christopher-Stine L, Corbett A, de Visser M, et al. Mortality and causes of death in patients with sporadic inclusion body myositis: survey study based on the clinical experience of specialists in Australia, Europe and the USA. J Neuromuscul Dis. 2016;3:67\u201375.","journal-title":"J Neuromuscul Dis"},{"key":"114_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/mus.25079","volume":"54","author":"C DeMuro","year":"2016","unstructured":"DeMuro C, Lewis S, Lowes L, Alfano L, Tseng B, Gnanasakthy A. Development of the sporadic inclusion body myositis physical functioning assessment (sIFA). Muscle Nerve. 2016;54:653\u20137.","journal-title":"Muscle Nerve"},{"key":"114_CR8","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/mus.25080","volume":"54","author":"V Williams","year":"2016","unstructured":"Williams V, Coles T, Gnanasakthy A, Demuro C, Yarr S, Williams N, et al. Psychometric validation of a patient-reported measure of physical functioning in sporadic inclusion body myositis: validation of the sIFA. Muscle Nerve. 2016;54:658\u201365.","journal-title":"Muscle Nerve"},{"key":"114_CR9","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/archoto.2010.129","volume":"136","author":"KW Altman","year":"2010","unstructured":"Altman KW, Yu G-P, Schaefer SD. Consequence of dysphagia in the hospitalized patient: impact on prognosis and hospital resources. Arch Otolaryngol Head Neck Surg. 2010;136:784\u20139.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"114_CR10","unstructured":"Life tables by WHO region - Europe [Internet]. WHO. [cited 2019 Feb 27]. Available from: \n                    http:\/\/apps.who.int\/gho\/data\/view.main.LIFEEUR?lang=en\n                    \n                  ."},{"key":"114_CR11","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.rmed.2006.01.001","volume":"100","author":"A Chetta","year":"2006","unstructured":"Chetta A, Zanini A, Pisi G, Aiello M, Tzani P, Neri M, et al. Reference values for the 6-min walk test in healthy subjects 20\u201350 years old. Respir Med. 2006;100:1573\u20138.","journal-title":"Respir Med"},{"key":"114_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.gaitpost.2014.10.002","volume":"41","author":"NM Salbach","year":"2015","unstructured":"Salbach NM, O\u2019Brien KK, Brooks D, Irvin E, Martino R, Takhar P, et al. Reference values for standardized tests of walking speed and distance: a systematic review. Gait Posture. 2015;41:341\u201360.","journal-title":"Gait Posture"},{"key":"114_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/jgs.13195","volume":"63","author":"C Minneci","year":"2015","unstructured":"Minneci C, Mello AM, Mossello E, Baldasseroni S, Macchi L, Cipolletti S, et al. Comparative study of four physical performance measures as predictors of death, incident disability, and falls in unselected older persons: the Insufficienza Cardiaca negli Anziani Residenti a Dicomano study. J Am Geriatr Soc. 2015;63:136\u201341.","journal-title":"J Am Geriatr Soc"},{"key":"114_CR14","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1212\/01.WNL.0000052991.70149.68","volume":"60","author":"U Nath","year":"2003","unstructured":"Nath U, Ben-Shlomo Y, Thomson RG, Lees AJ, Burn DJ. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology. 2003;60:910\u20136.","journal-title":"Neurology."},{"key":"114_CR15","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.parkreldis.2013.06.014","volume":"19","author":"C dell\u2019Aquila","year":"2013","unstructured":"dell\u2019Aquila C, Zoccolella S, Cardinali V, de Mari M, Iliceto G, Tartaglione B, et al. Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients. Parkinsonism Relat Disord. 2013;19:980\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"114_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jns.2004.07.013","volume":"225","author":"S Shintani","year":"2004","unstructured":"Shintani S, Shiigai T. Survival-determining factors in patients with neurologic impairments who received home health care in Japan. J Neurol Sci. 2004;225:117\u201323.","journal-title":"J Neurol Sci"},{"key":"114_CR17","first-page":"CR241","volume":"8","author":"HH Fernandez","year":"2002","unstructured":"Fernandez HH, Lapane KL. Predictors of mortality among nursing home residents with a diagnosis of Parkinson\u2019sdisease. Med Sci Monit. 2002;8:CR241\u20136.","journal-title":"Med Sci Monit"},{"key":"114_CR18","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1177\/1352458510379244","volume":"16","author":"M-L Sumelahti","year":"2010","unstructured":"Sumelahti M-L, Hakama M, Elovaara I, Pukkala E. Causes of death among patients with multiple sclerosis. Mult Scler. 2010;16:1437\u201342.","journal-title":"Mult Scler"},{"key":"114_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3121\/cmr.1.1.57","volume":"1","author":"LA Rolak","year":"2003","unstructured":"Rolak LA. Multiple sclerosis: It\u2019s not the disease you thought it was. Clin Med Res. 2003;1:57\u201360.","journal-title":"Clin Med Res"},{"key":"114_CR20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.msard.2013.12.003","volume":"3","author":"DW Kaufman","year":"2014","unstructured":"Kaufman DW, Reshef S, Golub HL, Peucker M, Corwin MJ, Goodin DS, et al. Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S. Mult Scler Relat Disord. 2014;3:364\u201371.","journal-title":"Mult Scler Relat Disord"},{"key":"114_CR21","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.msard.2015.08.005","volume":"4","author":"G Capkun","year":"2015","unstructured":"Capkun G, Dahlke F, Lahoz R, Nordstrom B, Tilson HH, Cutter G, et al. Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US Department of defense administrative claims database. Mult Scler Relat Disord. 2015;4:546\u201354.","journal-title":"Mult Scler Relat Disord"},{"key":"114_CR22","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.2147\/CIA.S107750","volume":"11","author":"LW Baijens","year":"2016","unstructured":"Baijens LW, Clav\u00e9 P, Cras P, Ekberg O, Forster A, Kolb GF, et al. European Society for Swallowing Disorders \u2013 European Union geriatric medicine society white paper: oropharyngeal dysphagia as a geriatric syndrome. Clin Interv Aging. 2016;11:1403\u201328.","journal-title":"Clin Interv Aging"},{"key":"114_CR23","unstructured":"Canadian Brain and Nerve Health Coalition, Canadian Institute for Health Information, Canadian Neurological Sciences Federation. The burden of neurological diseases, disorders and injuries in Canada. [Internet]. Ottawa: Canadian Neurological Sciences Federation = F\u00e9d\u00e9ration des Sciences neurologiques du Canada; 2007 [cited 2017 Feb 1]. Available from: \n                    http:\/\/public.eblib.com\/choice\/publicfullrecord.aspx?p=3252081"}],"container-title":["Theoretical Biology and Medical Modelling"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12976-019-0114-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12976-019-0114-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12976-019-0114-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:14:56Z","timestamp":1604621696000},"score":1,"resource":{"primary":{"URL":"https:\/\/tbiomed.biomedcentral.com\/articles\/10.1186\/s12976-019-0114-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["114"],"URL":"https:\/\/doi.org\/10.1186\/s12976-019-0114-4","relation":{},"ISSN":["1742-4682"],"issn-type":[{"type":"electronic","value":"1742-4682"}],"subject":[],"published":{"date-parts":[[2019,11,7]]},"assertion":[{"value":"5 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No patients were involved in the work and neither ethics approval nor consent to participate was required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individual person\u2019s data in any form is included in the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GC, SG, HS, AdV and VR are employees of Novartis. JS, TO and BA declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}